Alx Oncology Holdings (ALXO) Receivables - Other (2019 - 2020)
Alx Oncology Holdings (ALXO) reported Receivables - Other of -$527000.0 for Q4 2020, up 34.94% on a YoY basis from -$390548.9 in Q1 2020, and down 200.0% sequentially from $527000.0 in Q3 2020.
Alx Oncology Holdings (ALXO) Receivables - Other (2019 - 2020) Analysis & Trends
Alx Oncology Holdings (ALXO) has 2 years of Receivables - Other data on file, last reported at -$527000.0 in Q4 2020.
- For the quarter ending Q4 2020, Receivables - Other rose 34.94% year-over-year to -$527000.0; the trailing twelve-month figure through Dec 2020 stood at -$686000.0 (changed N/A YoY), and the FY2020 full-year result was -$536000.0, down 200.0% from the prior year.
- Receivables - Other declined to -$527000.0 in Q4 2020, from $527000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $655000.0 in Q1 2020 to a low of -$810000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -527,000.00 |
| Dec 31, 2020 | -527,000.00 |
| Sep 30, 2020 | 527,000.00 |
| Sep 30, 2020 | 527,000.00 |
| Jun 30, 2020 | 527,000.00 |
| Jun 30, 2020 | 527,000.00 |
| Mar 31, 2020 | 655,000.00 |
| Mar 31, 2020 | 655,000.00 |
| Dec 31, 2019 | -810,000.00 |
| Dec 31, 2019 | -810,000.00 |
| Sep 30, 2019 | -4,000.00 |
| Sep 30, 2019 | -4,000.00 |